BrainsWay Ltd. (NASDAQ:BWAY) Short Interest Update

BrainsWay Ltd. (NASDAQ:BWAY) saw a significant drop in short interest during the month of May. As of May 31st, there was short interest totalling 29,200 shares, a drop of 39.9% from the May 15th total of 48,600 shares. Based on an average daily trading volume, of 76,700 shares, the short-interest ratio is currently 0.4 days.

Institutional Trading of BrainsWay

A number of institutional investors have recently bought and sold shares of the business. Tucker Asset Management LLC raised its position in shares of BrainsWay by 1,686.9% in the fourth quarter. Tucker Asset Management LLC now owns 5,450 shares of the company’s stock valued at $35,000 after buying an additional 5,145 shares in the last quarter. Acadian Asset Management LLC bought a new stake in shares of BrainsWay during the 3rd quarter valued at $28,000. Quadrature Capital Ltd bought a new stake in shares of BrainsWay during the 4th quarter valued at $70,000. Virtu Financial LLC acquired a new stake in shares of BrainsWay during the 1st quarter worth $60,000. Finally, Jump Financial LLC bought a new position in shares of BrainsWay in the fourth quarter worth $207,000. Institutional investors own 30.11% of the company’s stock.

Wall Street Analyst Weigh In

BWAY has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of BrainsWay in a report on Wednesday, June 5th. Oppenheimer raised their target price on shares of BrainsWay from $10.00 to $11.00 and gave the stock an “outperform” rating in a research note on Thursday, May 9th.

BrainsWay Stock Performance

NASDAQ:BWAY traded down $0.08 during mid-day trading on Friday, hitting $6.13. 16,692 shares of the stock were exchanged, compared to its average volume of 78,808. The firm’s 50-day simple moving average is $5.61 and its 200 day simple moving average is $5.99. The stock has a market capitalization of $102.06 million, a price-to-earnings ratio of -68.10 and a beta of 1.23. BrainsWay has a fifty-two week low of $2.01 and a fifty-two week high of $7.61.

BrainsWay (NASDAQ:BWAY) last posted its earnings results on Wednesday, May 8th. The company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.02. BrainsWay had a negative return on equity of 3.98% and a negative net margin of 4.83%. The company had revenue of $9.10 million during the quarter, compared to the consensus estimate of $8.65 million. On average, analysts predict that BrainsWay will post 0.02 EPS for the current fiscal year.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.